UPDATE: Aegis Capital Initiates 3SBio at Buy on Revenue and Pipeline Quality

Aegis Capital initiated its coverage on 3SBio

with a Buy rating and a price target of $25 a share. Aegis Capital noted, "In our view, this firm is significantly underrated by the investment community and does not receive the credit it deserves for having built a substantial revenue base while also developing a broad and deep clinical-stage pipeline. In our view, this company is one of the highest-quality investments in the Chinese healthcare sector." 3SBio closed at $13.41 on Tuesday.